



## **Clinical Policy: Mosunetuzumab-axgb (Lunsumio, Lunsumio Velo)**

Reference Number: LA.PHAR.618

Effective Date: 09.29.23

Last Review Date: ~~02.13.26~~02.24.25

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

Formatted: Italian (Italy)

Formatted: Italian (Italy)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**\*\*Please note: This policy is for medical benefit\*\***

### **Description**

Mosunetuzumab-axgb (Lunsumio<sup>™</sup>, Lunsumio Velo<sup>™</sup>) is a bispecific CD20-directed CD3 T-cell engager antibody.

### **FDA Approved Indication(s)**

Lunsumio ~~is~~and Lunsumio Velo are indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that member has met all approval criteria.*

It is the policy of Louisiana Healthcare Connections<sup>®</sup> that Lunsumio ~~is~~and Lunsumio Velo are medically necessary when the following criteria are met:

### **I. Initial Approval Criteria**

#### **A. Follicular Lymphoma** (must meet all):

1. Diagnosis of relapsed or refractory follicular lymphoma characterized as both of the following (a and b):
  - a. Grade 1, 2 or 3a (low grade or slow growing);
  - b. Presence of at least one bi-dimensionally measurable lesion ( $\geq 1.5$  cm in its largest dimension for nodal lesions, or  $\geq 1.0$  cm in its largest dimension for extranodal lesions);
2. Prescribed by or in consultation with an oncologist or a hematologist;
3. Age  $\geq 18$  years;
4. Member has received at least two prior lines of systemic therapy including all of the following (a and b):
  - a. One anti-CD20-directed therapy (e.g., rituximab, Arzerra<sup>®</sup>, Gazyva<sup>®</sup>);
  - b. One alkylating agent (e.g., bendamustine, cyclophosphamide);
5. Member does not have a known current or past central nervous system (CNS) lymphoma, or a history of CNS disease (e.g., stroke/transient ischemic attack with

## CLINICAL POLICY

### Mosunetuzumab-axgb

residual neurologic deficits; epilepsy with seizures in the past 2 years; CNS vasculitis or neurodegenerative disease);

6. Request is for up to 8 treatment cycles of 21 days each:

~~6-7~~. Dose does not exceed one of the following (a, b, or ~~bc~~):\*

a. ~~A#~~For Lunsumio, all of the following (i, ii, and iii):

i. Cycle 1:

- a) Day 1: 1 mg;
- b) Day 8: 2 mg;
- c) Day 15: 60 mg;

ii. Cycle 2: Day 1: 60 mg;

iii. Cycles 3+: Day 1: 30 mg;

b. For Lunsumio Velo, both of the following (i and ii):

i. Cycle 1:

- a) Day 1: 5 mg;
- b) Day 8: 45 mg;
- c) Day 15: 45 mg;

ii. Cycles 2+: Day 1: 45 mg;

~~b-c~~. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 9 months (8 treatment cycles of 21 days each)**

### **B. B-Cell Lymphoma (off-label) (must meet all):**

1. Diagnosis of one of the following B-cell lymphomas (a, b, c, or d):

- a. Diffuse large b-cell lymphoma;
- b. High-grade b-cell lymphomas;
- c. HIV-related b-cell lymphomas;
- d. Post-transplant lymphoproliferative disorders;

2. Request is for one of the following:

- a. Second-line and subsequent therapy;
- b. After completion of first-line therapy or primary refractory disease in non-candidates for CAR T-cell therapy or if no intention to proceed to transplant;
- c. Alternative systemic therapy (if not previously used) for relapsed or refractory disease;

3. Prescribed in combination with Polivy<sup>®</sup>;

4. Request is for up to 8 treatment cycles of 21 days each;

5. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).\*

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 9 months (8 treatment cycles of 21 days each)**

### **B-C. Other diagnoses/indications (must meet 1 or 2):**

**CLINICAL POLICY**  
**Mosunetuzumab-axgb**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53.

**II. Continued Therapy**

**A. ~~Follicular Lymphoma~~ All Indications in Section I** (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit or documentation supports that member is currently receiving Lunsumio for a covered indication and has received this medication for at least 30 days;
2. Member meets one of the following (a or b):
  - a. Received 8 initial treatment cycles and ~~needs further therapy due to incomplete or partial response; both of the following (i and ii):~~
    - i. Member needs further therapy due to incomplete or partial response;
    - ii. Request is for up to 9 additional continued therapy cycles (total of 17 cycles between the initial and continued therapy);
  - b. Did not receive 8 initial treatment cycles, and wishes to resume therapy; to complete the 8 initial treatment cycles\*;
    - b- \* Re-authorization is required if treatment beyond 8 initial treatment cycles is requested;
3. Member is responding positively to therapy;
4. If request is for a dose increase, request meets one of the following (a, b, or ~~b-c~~):\*
  - a. All For Lunsumio, all of the following (i, ii and iii):
    - i. Cycle 1:
      - a) Day 1: 1 mg;
      - b) Day 8: 2 mg;
      - c) Day 15: 60 mg;
    - ii. Cycle 2: Day 1: 60 mg;
    - iii. Cycles 3+: Day 1: 30 mg;
  - b. For Lunsumio Velo, both of the following (i and ii):
    - i. Cycle 1:
      - a) Day 1: 5 mg;
      - b) Day 8: 45 mg;
      - c) Day 15: 45 mg;
    - ii. Cycles 2+: Day 1: 45 mg;
  - ~~b-c.~~ New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*\*Prescribed regimen must be FDA-approved or recommended by NCCN*

**Approval duration: 12 months (see comments below)**

- **For members who received 8 initial treatment cycles, 9 additional continued therapy cycles will be approved for the total of 17 cycles between the initial and continued therapy.**

Formatted: Font: 10 pt, Italic  
 Formatted: Indent: Left: 1", No bullets or numbering

Formatted: Indent: Left: 0.75", Numbered + Level: 1 + Numbering Style: a, b, c, ... + Start at: 1 + Alignment: Left + Aligned at: 1" + Indent at: 1.25"

Formatted: Tab stops: 1.25", Left

Formatted: Indent: Left: 1.25", Numbered + Level: 1 + Numbering Style: a, b, c, ... + Start at: 1 + Alignment: Left + Aligned at: 3.25" + Indent at: 3.5"

Formatted: Tab stops: 1.25", Left

Formatted: Indent: Left: 0.75", Numbered + Level: 1 + Numbering Style: a, b, c, ... + Start at: 1 + Alignment: Left + Aligned at: 1" + Indent at: 1.25"

**CLINICAL POLICY**

**Mosunetuzumab-axgb**

- **For members who did not receive 8 initial treatment cycles but wish to resume therapy, approval will be granted to complete the 8 initial treatment cycles after which re-authorization for continued therapy will be required.**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 2 above does not apply, refer to the off-label use policy LA.PMN.53.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy ~~LA.PMN.53~~ LA.PMN.53.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

CNS: central nervous system ~~ICANS: immune effector cell associated neurotoxicity~~  
~~CRS: cytokine release syndrome~~ NCCN: National Comprehensive Cancer Network  
 FDA: Food and Drug Administration  
~~FL: follicular lymphoma~~

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.*

| Drug Name  | Dosing Regimen | Dose Limit/ Maximum Dose |
|--|----------------|--------------------------|
| <u>Examples of first-line, second-line, and subsequent therapies:</u> <ul style="list-style-type: none"> <li>• bendamustine + (Gazyva® (obinutuzumab) or rituximab)</li> <li>• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) ± (Gazyva® (obinutuzumab) or rituximab)</li> <li>• CVP (cyclophosphamide, vincristine, prednisone) + (Gazyva® (obinutuzumab) or rituximab)</li> </ul> | Varies         | Varies                   |
| <u>Single-agent examples:</u> rituximab; Leukeran® (chlorambucil) ± rituximab; cyclophosphamide ± rituximab; Revlimid® (lenalidomide) ± (Gazyva® (obinutuzumab) or rituximab); Aliqopa® (copanlisib); Gazyva® (obinutuzumab), Tazverik™ (tazemetostat)   |                |                          |

## CLINICAL POLICY

### Mosunetuzumab-axgb

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

#### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): ~~None~~ reported
- Boxed warning(s): ~~Cytokine~~ cytokine release syndrome including serious or life-threatening reactions, ~~and neurologic toxicity including immune effector cell associated neurotoxicity~~

## V. Dosage and Administration

| Indication                                 | Dosing Regimen   | Maximum Dose  |
|--|--|---|
| Follicular<br><del>Lymphoma</del> lymphoma | <p><u>Administer for 8 cycles (cycle length = 21 days) unless patients experience unacceptable toxicity or disease progression.</u></p> <ul style="list-style-type: none"> <li>• <u>For patients who achieve a complete response, no further treatment beyond 8 cycles is required.</u></li> <li>• <u>For patients who achieve a partial response or have stable disease in response to treatment after 8 cycles, an additional 9 cycles of treatment (17 cycles total) should be administered, unless the patient experiences unacceptable toxicity or disease progression.</u></li> </ul> <p><u>Lunsumio*: IV</u><br/>           Cycle 1*:<br/> <ul style="list-style-type: none"> <li>• Day 1: 1 mg</li> <li>• Day 8: 2 mg</li> <li>• Day 15: 60 mg</li> </ul>           Cycle 2: Day 1: 60 mg<br/>           Cycles 3+: Day 1: 30 mg</p> <p><u>Lunsumio Velo*: SC</u><br/>           Cycle 1:<br/> <ul style="list-style-type: none"> <li>• <u>Day 1: 5 mg</u></li> <li>• <u>Day 8: 45 mg</u></li> <li>• <u>Day 15: 45 mg</u></li> </ul>           Cycles 2+: Day 1: 45 mg</p> | <p><u>Lunsumio: 60 mg/dose intravenous infusion</u></p> <p><u>Lunsumio Velo: 45 mg/dose</u></p> |

\* Refer to prescribing information for details on administration duration for each cycle, recommended premedications, and dose modifications for adverse reactions.

## VI. Product Availability

## CLINICAL POLICY

### Mosunetuzumab-axgb

~~Solution for intravenous infusion in a single-dose vial:~~

- ~~• 1 mg/mL (total 1 mL vial volume)~~
- ~~• 30 mg/30 mL (total 30 mL vial volume)~~

| Drug Name                             | Availability  |
|---------------------------------------|---|
| Mosunetuzumab-axgb<br>(Lunsumio)      | Solution for intravenous infusion in single-dose vials: <ul style="list-style-type: none"> <li>• 1 mg/mL (total 1 mL vial volume)</li> <li>• 30 mg/30 mL (total 30 mL vial volume)</li> </ul>     |
| Mosunetuzumab-axgb<br>(Lunsumio Velo) | Solution for subcutaneous injection in single-dose vials: <ul style="list-style-type: none"> <li>• 5 mg/0.5 mL (total 0.5 mL vial volume)</li> <li>• 45 mg/mL (total 1 mL vial volume)</li> </ul> |

## VII. References

1. Lunsumio Prescribing Information. South San Francisco, CA: Genentech, Inc.; December 2022~~2025~~. Available at: [www.lunsumio.com](http://www.lunsumio.com). Accessed ~~October 17, 2024~~[January 14, 2026](#).
- ~~1-2~~2. Lunsumio Velo Prescribing Information. South San Francisco, CA: Genentech, Inc.; December 2025. Available at: [www.lunsumio.com](http://www.lunsumio.com). Accessed [January 14, 2026](#).
- ~~2-3~~3. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: [http://www.nccn.org/professionals/drug\\_compendium](http://www.nccn.org/professionals/drug_compendium). Accessed ~~October 23, 2024~~[January 2026](#).
- ~~3-4~~4. National Comprehensive Cancer Network. B-Cell Lymphomas Version 3.~~2024~~[2025](#). Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf). Accessed ~~October 23, 2024~~[November 4, 2025](#).
- ~~4-5~~5. ClinicalTrials.gov. A safety, efficacy, and pharmacokinetic study of BTCT4465A (mosunetuzumab) as a single agent and combined with atezolizumab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Available at: <https://www.clinicaltrials.gov/ct2/show/record/NCT02500407>. Accessed ~~October 23, 2024~~[November 4, 2025](#).
- ~~5-6~~6. Budde LE, Assouline S, Sehn LH, *et al*. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory b-cell lymphomas: phase I dose-escalation study. *J Clin Oncol*. 2022;40(5):481-491.
- ~~6-7~~7. Budde LE, Sehn LH, Matasar M, *et al*. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. *Lancet Oncol*. 2022;23(8):1055-1065.

## Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| HCPCS Codes | Description                         |
|-------------|-------------------------------------|
| J9350       | Injection, mosunetuzumab-axgb, 1 mg |

## CLINICAL POLICY

### Mosunetuzumab-axgb

| Reviews, Revisions, and Approvals   | Date            | LDH Approval Date |
|---|-----------------|-------------------|
| Policy created  | 05.01.23        | 08.28.23          |
| Annual review: added HCPCS code [J9350]; references reviewed and updated.   | 03.25.24        | 05.23.24          |
| Annual review: no significant changes; updated Appendix B with additional therapeutic options per NCCN guidelines; references reviewed and updated.                     | 02.24.25        | <u>05.19.25</u>   |
| <u>Annual review: per NCCN Compendium added off-label use in additional B-cell lymphomas subtypes; references reviewed and updated. Added Lunsumio Velo to criteria</u> | <u>02.13.26</u> |                   |

#### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

## CLINICAL POLICY

### Mosunetuzumab-axgb

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2026 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.